Skip to main content
. 2025 Jun 27;17(13):2166. doi: 10.3390/cancers17132166
MM Multiple Myeloma
MBD Myeloma bone disease
ZA Zoledronic Acid
ONJ Osteonecrosis of the Jaw
VGPR Very good partial response
OPG Osteoprotegerin
RT Radiotherapy
NGF Nerve Growth Factor
SNRIs Serotonin-norepinephrine reuptake inhibitors
SMM Smoldering multiple my
MGUS monoclonal gammopathy of undetermined significance
OS Overall survival
PFS Progression-free survival
ASCO American Society of Clinical Oncology
IMWG International Myeloma Working Group
NCCN National Comprehensive Cancer Network